Galmed Pharmaceuticals said preclinical prostate cancer results showed that combining Aramchol with Xtandi (enzalutamide) increased cancer cell death by 3-4 times compared with Xtandi alone. The company presented the data as an initial readout from its prostate oncology work. The updated description clarifies that the reported effect came from combination treatment in tested models, rather than from a standalone Aramchol-versus-enzalutamide comparison.